David Bourget (Western Ontario)
David Chalmers (ANU, NYU)
Rafael De Clercq
Jack Alan Reynolds
Learn more about PhilPapers
Kennedy Institute of Ethics Journal 21 (1):51-78 (2011)
Randomized and double-blind clinical trials are widely regarded as the most reliable way of studying the effects of medical interventions. According to received wisdom, if a new drug or treatment is to be accepted in clinical practice, its safety and efficacy must first be demonstrated in such trials. For ethical and scientific reasons, it is generally considered necessary to monitor a trial in various ways as it proceeds and to analyze data as they accumulate. Monitoring and interim analyses are often conducted by a so-called data monitoring committee (DMC), a group of experts independent of both sponsors and investigators. On the basis of DMC recommendations, sponsors sometimes decide to discontinue trials ..
|Keywords||No keywords specified (fix it)|
|Categories||categorize this paper)|
Setup an account with your affiliations in order to access resources via your University's proxy server
Configure custom proxy (use this if your affiliation does not provide a proxy)
|Through your library|
References found in this work BETA
No references found.
Citations of this work BETA
No citations found.
Similar books and articles
Erik Malmqvist Niklas Juth Niels Lynöe Gert Helgesson (2011). Early Stopping of Clinical Trials: Charting the Ethical Terrain. Kennedy Institute of Ethics Journal 21 (1):51-78.
David Buchanan & Franklin G. Miller (2005). Principles of Early Stopping of Randomized Trials for Efficacy: A Critique of Equipoise and an Alternative Nonexploitation Ethical Framework. Kennedy Institute of Ethics Journal 15 (2):161-178.
Roger Stanev (2011). Statistical Decisions and the Interim Analyses of Clinical Trials. Theoretical Medicine and Bioethics 32 (1):61-74.
Roger Stanev (2012). The Epistemology and Ethics of Early Stopping Decisions in Randomized Controlled Trials. Dissertation, University of British Columbia
Jeremy Sugarman (2004). Using Empirical Data to Inform the Ethical Evaluation of Placebo Controlled Trials. Science and Engineering Ethics 10 (1):29-35.
Sven Ove Hansson (2006). Uncertainty and the Ethics of Clinical Trials. Theoretical Medicine and Bioethics 27 (2):149-167.
Lawrence Scahill, Mary Solanto & Joseph McGuire (2008). The Science and Ethics of Placebo in Pediatric Psychopharmacology. Ethics and Behavior 18 (2 & 3):266 – 285.
Franklin G. Miller & Howard Brody (2002). What Makes Placebo-Controlled Trials Unethical? American Journal of Bioethics 2 (2):3 – 9.
Peter Graeme Hobbins (2005). Compromised Ethical Principles in Randomised Clinical Trials of Distant, Intercessory Prayer. Journal of Bioethical Inquiry 2 (3):142-152.
Frederic Gilbert, Alexander R. Harris & Robert M. I. Kapsa (2012). Efficacy Testing as a Primary Purpose of Phase 1 Clinical Trials: Is It Applicable to First-in-Human Bionics and Optogenetics Trials? AJOB Neuroscience 3 (2):20-22.
Lisa R. Stines & Norah C. Feeny (2008). Unique Ethical Concerns in Clinical Trials Comparing Psychosocial and Psychopharmalogical Interventions. Ethics and Behavior 18 (2 & 3):234 – 246.
Maurie Markman (2004). The Research Misconception. International Journal of Applied Philosophy 18 (2):241-252.
David Teira (2011). Bayesian Versus Frequentist Clinical Trials. In Gifford Fred (ed.), Philosophy of Medicine [Handbook of Philosophy of Science, vol. 16],. Elsevier.
Bernard Lo & Lindsay Parham (2010). Resolving Ethical Issues in Stem Cell Clinical Trials: The Example of Parkinson Disease. Journal of Law, Medicine and Ethics 38 (2):257-266.
Added to index2011-05-05
Total downloads22 ( #81,803 of 1,099,914 )
Recent downloads (6 months)11 ( #21,225 of 1,099,914 )
How can I increase my downloads?